Latest stories on STRO
STRO Maintained by Barclays -- Price Target Raised to $57.00
GuruFocus63 · neutralanalyst
Sutro Biopharma price target lowered to $25 from $60 at Wedbush
The Fly28 · bearishanalyst
Sutro Biopharma price target raised to $57 from $56 at Barclays
The Fly61 · neutralanalyst
Sutro Biopharma Reports Q3 Revenue Miss, Focuses on ADC Pipeline Progress (STRO)
GuruFocus34 · bearishearnings
Sutro Biopharma GAAP EPS of -$1.90 misses by $0.22, revenue of $9.1M misses by $5.02M
Seeking Alpha34 · bearishearnings
Sutro Biopharma reports Q3 EPS ($1.90), consensus ($1.96)
The Fly44 · neutralearnings
SUTRO BIOPHARMA, INC. (STRO) files 8-K: Items 2.02, 9.01
SEC 8-K50 · neutralgeneral
Sutro Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
GlobeNewswire50 · neutralearnings
3 ‘Strong Buy’ High-Risk Stocks That Could Offer Mouth-Watering Returns
TipRanks64 · neutralanalyst
Sutro Biopharma to Participate in Upcoming Investor Conferences
GlobeNewswire52 · neutralproduct/pr
Sutro Biopharma to Participate in Upcoming Investor Conferences
Business Insider52 · neutralproduct/pr
Sutro’s New Phase 1 Cancer Study Puts STRO-006 in the Spotlight
TipRanks58 · neutralproduct/pr
Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid Tumors
GlobeNewswire61 · neutralproduct/pr
Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid Tumors
Business Insider58 · neutralproduct/pr
H.C. Wainwright reiterates Sutro Biopharma stock rating at buy
Investing.com Analyst Ratings58 · neutralanalyst
Sutro Biopharma highlights STRO-004 safety and dual-payload STRO-227 at World ADC Conference
MarketChameleon58 · neutralproduct/pr
Sutro Biopharma spotlights STRO-004 clinical safety and STRO-227 dual-payload data at World ADC Conference
October 12, 2026
MarketChameleon58 · neutralproduct/pr
Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference
GlobeNewswire53 · neutralproduct/pr
Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference
Business Insider53 · neutralproduct/pr
Sutro Biopharma appoints Donigian as SVP, Business Development
The Fly55 · neutralgeneral
Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development
GlobeNewswire55 · neutralgeneral
UBS upgrades Straumann to ’buy’, ending five-year cautious stance
Investing.com Markets61 · neutralanalyst
H.C. Wainwright calls Sutro drop ‘an overreaction’ to limited STRO-004 data
The Fly58 · neutralanalyst
Sutro Biopharma price target lowered to $34 from $41 at Citizens
The Fly38 · neutralanalyst
Citizens cuts Sutro Biopharma stock price target on revenue miss
Investing.com Analyst Ratings34 · bearishanalyst